The Obesity ETF (SLIM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
On Wednesday, Novo Nordisk A/S NVO and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Tyrzepatide seems more effective than semaglutide, but the market for slimming drugs is quite large for both. Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly seems too pricey right now. In contrast, Novo Nordisk seems rather cheap given. The number of obese people in the world is bound to increase unless there is a radical change in habits. This factor is the main long-term growth driver.
Lilly's Obesity Drug Zepbound To Be Key Health Cost Driver For 2025
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers, employers and government health programs who cover it in 2025.
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. The post Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. RYTM, a developer of treatment for rare obesity disorders.
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. Tirzepatide's clinical trial updates were very positive this year, including the results from the head-to-head showing superiority trial to Novo Nordisk's semaglutide. With CagriSema underperforming expectations this week, the risk of a product superior to tirzepatide coming to market in the next few years is greatly reduced.
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped The post Novo Nordisk Dives On CagriSegma Obesity Drug Trial.
Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.
The experimental obesity drug CagriSema disappointed investors.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk's dominance in the weight-loss market.
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
On Friday, BioAge Labs Inc. BIOA announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
